PACB

#3014
Pacific Biosciences of California, Inc. - Common Stock
1.4 0 USD
-0.10%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.40
1.40
Jahresspanne
1.07
2.73
Tagesänderung
-9.68%
Monatliche Änderung
-4.76%
6 month change
-12.50%
Jahresänderung
+7.69%
Vorheriger Schlusskurs
1.5 5
Open
1.4 0
Tief
1.4 0
Hoch
1.4 0
Volumen
53
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, 26 April 2017

Full document

Business Context and Reporting Period

Company: Pacific Biosciences of California, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: April 26, 2017
Reporting Period: First fiscal quarter ended March 31, 2017

This filing serves as a notification that the company announced its financial results for the first quarter of 2017. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference but explicitly stated as "furnished" rather than "filed" under the Exchange Act.

Key Financial Metrics

The provided text is a cover sheet for the 8-K filing and does not contain specific financial data points. The following metrics are not present in the source text:

  • Revenue
  • Net Profit or Loss
  • Cash Flow
  • Profit Margins
  • Debt Levels
  • Liquidity Position

Investors must refer to the attached Exhibit 99.1 (Press Release) for these specific values.

Material Changes

The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. It only confirms the announcement of the Q1 2017 results.

Guidance, Outlook, and Risks

Management Commentary: The filing references a press release containing the announcement but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the provided text.

Important Facts for Investor Verification

  • Source of Data: All financial figures and operational details are located in Exhibit 99.1 (Press Release), not in the body of this 8-K form.
  • Filing Status: The financial information is "furnished" and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference in other filings unless expressly stated.
  • Reporting Period: Verify that the data in the press release corresponds to the quarter ended March 31, 2017.
  • Signatory: The report was signed by Susan K. Barnes, Executive Vice President, Chief Financial Officer & Principal Accounting Officer.

Nachrichten